ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009
Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 9 syntheses or guidelines pooled it, 282 citations in OpenAlex.
- Pooled it
- Pooled it
- The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis.British journal of cancer · 2017Pooled it
- Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma.Nature genetics · 2015Pooled it
- Obesity and cancer: the role of vitamin D.BMC cancer · 2014Pooled it
- Vitamin D supplements and cancer incidence and mortality: a meta-analysis.British journal of cancer · 2014Pooled it
- Vitamin D receptor polymorphisms in patients with cutaneous melanoma.International journal of cancer · 2012Pooled it
- Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review.The oncologist · 2011Pooled it
- Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data.European journal of cancer (Oxford, England : 1990) · 2009Pooled it
- Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial.Nutrients · 2021Trial
- 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.British journal of cancer · 2018Trial
- Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.BMC cancer · 2017Trial
- Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Trial
- Trial
- Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- Dietary vitamin D intake and serum 25-hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients.International journal of cancer · 2011Trial
- An evaluation of pathology foundation models with weakly supervised learning for BRAF mutation prediction in melanoma whole slide images.Frontiers in medical technology · 2026Article
- Vitamin D-induced mechanisms in cancer prevention and therapy: Recent advances and future opportunities.Animal models and experimental medicine · 2025Review
- Vitamin D and Inhibition of Melanogenesis: Examination of Liposomal Vitamin D Nanocarrier Anti-Melanogenesis Activity on B16 F10 Cell Line.Food science & nutrition · 2025Article
- Exploration in association between vitamin D and cutaneous melanoma and explainable machine learning prediction.Frontiers in oncology · 2025Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
20 authors at 1 institution in 1 country.
Funding
Abstract
purposeA cohort study was carried out to test the hypothesis that higher vitamin D levels reduce the risk of relapse from melanoma.
methodsA pilot retrospective study of 271 patients with melanoma suggested that vitamin D may protect against recurrence of melanoma. We tested these findings in a survival analysis in a cohort of 872 patients recruited to the Leeds Melanoma Cohort (median follow-up, 4.7 years).
resultsIn the retrospective study, self-reports of taking vitamin D supplements were nonsignificantly correlated with a reduced risk of melanoma relapse (odds ratio = 0.6; 95% CI, 0.4 to 1.1; P = .09). Nonrelapsers had higher mean 25-hydroxyvitamin D(3) levels than relapsers (49 v 46 nmol/L; P = .3; not statistically significant). In the cohort (prospective) study, higher 25-hydroxyvitamin D(3) levels were associated with lower Breslow thickness at diagnosis (P = .002) and were independently protective of relapse and death: the hazard ratio for relapse-free survival (RFS) was 0.79 (95% CI, 0.64 to 0.96; P = .01) for a 20 nmol/L increase in serum level. There was evidence of interaction between the vitamin D receptor (VDR) BsmI genotype and serum 25-hydroxyvitamin D(3) levels on RFS.
conclusionResults from the retrospective study were consistent with a role for vitamin D in melanoma outcome. The cohort study tests this hypothesis, providing evidence that higher 25-hydroxyvitamin D(3) levels, at diagnosis, are associated with both thinner tumors and better survival from melanoma, independent of Breslow thickness. Patients with melanoma, and those at high risk of melanoma, should seek to ensure vitamin D sufficiency. Additional studies are needed to establish optimal serum levels for patients with melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.